Presentation is loading. Please wait.

Presentation is loading. Please wait.

3100A Ventilator. VIASYS Healthcare, Inc. 3100A Ventilator Approved in 1991 for Neonatal Application for the treatment of all forms of respiratory failure.

Similar presentations


Presentation on theme: "3100A Ventilator. VIASYS Healthcare, Inc. 3100A Ventilator Approved in 1991 for Neonatal Application for the treatment of all forms of respiratory failure."— Presentation transcript:

1 3100A Ventilator

2 VIASYS Healthcare, Inc. 3100A Ventilator Approved in 1991 for Neonatal Application for the treatment of all forms of respiratory failure. Approved in 1995 for Pediatric Application, with no upper “weight limit”. For treating selected patients failing conventional ventilation.

3 VIASYS Healthcare, Inc. Theory of Operation Oxygenation is primarily controlled by the Mean Airway Pressure (Paw) and the FiO 2 Ventilation is primarily determined by the stroke volume (Delta-P) and the frequency of the ventilator.

4 VIASYS Healthcare, Inc. SensorMedics 3100A Electrically powered, electronically controlled piston-diaphragm oscillator Paw of 3 - 45 cmH 2 O Pressure Amplitude from 8 - 110 cmH 2 O Frequency of 3 - 15 Hz Inspiratory Time 30% - 50% Flow rates from 0 - 40 LPM

5 VIASYS Healthcare, Inc. Paw is created by a continuous bias flow of gas past the resistance (inflation) of the balloon on the mean airway pressure control valve.

6 VIASYS Healthcare, Inc. Principle of the SM 3100A HFOV “Super-CPAP” system to maintain lung volume

7 VIASYS Healthcare, Inc. Oxygenation The Paw is used to inflate the lung and optimize the alveolar surface area for gas exchange. Paw = Lung Volume

8 VIASYS Healthcare, Inc. Optimizing Hemodynamics PVR is increased with: – Atelectasis Loss of support for extra- alveolar vessels –Over expansion Compression of alveolar capillary bed The lung must be recruited, but guard against over expanding.

9 VIASYS Healthcare, Inc. Ventilation

10 VIASYS Healthcare, Inc. Primary control of CO 2 is by the stroke volume produced by the Power Setting.

11 VIASYS Healthcare, Inc. Alveolar ventilation during CMV is defined as F x Vt Alveolar Ventilation during HFV is defined as F x Vt 2 Therefore, changes in volume delivery (as a function of Delta-P, Freq., or % Insp. Time) have the most significant affect on CO 2 elimination

12 VIASYS Healthcare, Inc. Pressure transmission Gerstmann D.

13 VIASYS Healthcare, Inc. Pressure transmission HFOV P T proximal trachea alveoli

14 VIASYS Healthcare, Inc. Secondary control of PaCO 2 is the set Frequency.

15 VIASYS Healthcare, Inc. Regulation of stroke volume The stroke volume will increase if –The amplitude increases (higher delta P) –The frequency decreases (longer cycle time) Stroke volume

16 VIASYS Healthcare, Inc. The % Inspiratory Time controls the time for piston displacement, controlling CO 2 elimination. Increasing % Inspiratory Time will also affect lung recruitment by increasing delivered Paw.

17 VIASYS Healthcare, Inc. Inspiratory / Expiratory Ratio I/E Ratio adjustable with Inspiratory time control Inspiratory time = Forward movement piston Expiratory time = Backward movement piston Backward movement piston = active exhalation ! Recommended Insp. time = 33% (prevents air-trapping) Inspiratory time adjustable: 30% - 50% + -- 30% 70%

18 VIASYS Healthcare, Inc.

19

20

21

22

23 Patient Circuit Calibration

24 VIASYS Healthcare, Inc. Ventilator Performance Check


Download ppt "3100A Ventilator. VIASYS Healthcare, Inc. 3100A Ventilator Approved in 1991 for Neonatal Application for the treatment of all forms of respiratory failure."

Similar presentations


Ads by Google